This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           February 25, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

Everolimus plus letrozole effective in recurrent endometrial carcinoma
Healio — HemOnc Today
The combination of everolimus and letrozole yielded high rates of objective response and clinical benefit in patients with recurrent endometrial carcinoma, according to results of a phase 2 study published in the Journal of Clinical Oncology. In prior studies, hormonal therapy and single-agent treatment with mTOR inhibitors such as everolimus have demonstrated effectiveness in women with metastatic or recurrent endometrial carcinoma.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




SGO NEWS


Sunrise Seminars at the SGO Annual Meeting
SGO is offering a total of six Sunrise Seminars during the SGO Annual Meeting on Women's Cancer in Chicago on March 28-31, from "Ergonomic Efficiency in the OR" to "Controversies on Tissue Morcellation and Extraction." Learn more about all of these one-hour sessions and register today.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


ROBOTICS


ACOG issues guidelines for robot-assisted gynecologic surgery
Medscape (Free login required)
Robot-assisted surgery has grown more than 25 percent annually, but committee recommendations from the American College of Obstetricians and Gynecologist (ACOG) note there are no high-quality data on cost, patient outcomes, or safety to support its rapid adoption for gynecologic surgery. Well-designed randomized controlled trials (RCTs) or "comparably rigorous non-randomized prospective trials" are needed to establish the benefits and risks of robot-assisted gynecologic surgery, the Committee on Gynecologic Practice for the Society of Gynecologic Surgeons said in an opinion published in the March issue of Obstetrics & Gynecology.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


CERVICAL CANCER


Vaccine that targets 9 strains of HPV boosts cancer protection, study says
Los Angeles Times
When it comes to HPV vaccines, more protection is better. A new version of the vaccine that fights nine strains of human papillomavirus offered greater cancer protection for women than the earlier one that targets only four, researchers reported in the New England Journal of Medicine. A multinational study involving thousands of women found that the nonavalent vaccine worked as well as the original vaccine at preventing infections caused by HPV-16 and HPV-18. Together, these strains are responsible for 70 percent of all cases of cervical cancer.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Colposcopic cervical biopsies: More is usually better
Medscape (Free login required)
Many clinicians take only one ectocervical biopsy at the time of colposcopy. Recent reports provide good-quality data to guide us regarding the number of biopsies we should perform to best detect high-grade cervical pathology requiring treatment. One report published in late 2014 focused on the value of a single, random cervical biopsy when colposcopy was performed for abnormal cytology, high-risk HPV, or both, but did not reveal cervical lesions. Among almost 2800 such women, biopsy was normal in 90 percent, revealed CIN1 in 6 percent, and CIN2 or worse in 3 percent.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




OVARIAN CANCER


Two genes that trigger most severe form of ovarian cancer are pinpointed
OncologyNurseAdvisor
In the battle against ovarian cancer, researchers have created the first mouse model of the worst form of the disease and found a potential route to better treatments and much-needed diagnostic screens. Their study was published in Nature Communications. The genetics researchers discovered how two genes interact to trigger cancer and then spur on its development. "It's an extremely aggressive model of the disease, which is how this form of ovarian cancer presents in women," said study leader Terry Magnuson, PhD.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


  FEATURED COMPANIES
Uncover Hereditary Cancer Risk for Your Patients
The average OB/GYN has 400 patients who meet criteria for further evaluation of hereditary cancer syndrome. Learn how to identify high-risk patients.
Advertise here!

To find out how to feature your company in the SGO News Brief and other advertising opportunities, Contact Geoffrey Forneret at 469-420-2629.
MORE


MORCELLATION


Two new studies add to scrutiny of gynecology tool
The Wall Street Journal (Subscription required)
New research is adding to scrutiny of a surgical tool called the laparoscopic power morcellator that the Food and Drug Administration has warned against using in a vast majority of cases because of its potential to spread hidden cancer in common gynecological procedures, according to a study was published online Feb. 19 in JAMA Oncology. The University of Michigan said that researchers at its health system had found that of women who had hysterectomies for uterine growths called fibroids, one in 368 had an undetected uterine sarcoma, which could be worsened with a morcellator if doctors use that technique.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MISS AN ISSUE OF WOMEN'S CANCER NEWS?
Visit the SGO Women's Cancer News archive page.


SURVIVORSHIP


US cancer survival rates improving
Reuters
The proportion of people surviving years after a cancer diagnosis is improving, according to a new analysis. Men and women ages 50 to 64, who were diagnosed in 2005 to 2009 with a variety of cancer types, were 39 to 68 percent more likely to be alive five years later, compared to people of the same age diagnosed in 1990 to 1994, researchers found in a study published in JAMA Oncology. “Pretty much all populations improved their cancer survival over time,” said Dr. Wei Zheng, the study’s senior author from Vanderbilt University in Nashville.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

Feb. 18, 2015
Feb. 11, 2015
Feb. 4, 2015
Jan. 28, 2015






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063